![](/wp-content/uploads/2022/06/June-1-2022-Blast-Draft.png)
$599
First Cagrisema Pivotal Trial on CT.gov; Lannett Doses 50% of Patients in Bs-glargine Pivotal Trial
Two cardiometabolic-related news items have been observed: The first trial in the cagrisema pivotal program, called “REDEFINE,” has been observed (view CT.gov record); and Lannett provided updates to its bs-glargine pivotal trial (press release). Below, FENIX provides highlights and insights for the respective new items.